Summary
204 patients with biopsy-proven CAH were observed for at least one year with periodic examinations including a second liver biopsy for each patient. Patients were assigned at random to a group left untreated or treated with either azathioprine 100 mg daily, or prednisolone (Dutimelan 8 15*), or prednisolone plus azathioprine 50 mg daily. The outcome, assessed on clinical, biochemical and histological parameters, was correlated to the presence or absence of HBeAg and its antibody. No treatment was effective in HBeAg-positive patients whereas, among anti-HBe-positive patients, those who were treated with the association of steroids and azathioprine more frequently showed improvement and less frequently deteriorated (p<0.01) than untreated patients. Thus, HBsAg/anti-HBe-positive patients with CAH may be treated with the combination of these drugs, even though many side-effects may occur and there are frequent relapses after discontinuation of treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cook G. C., Mulligan R., Sherlock S.: Controlled prospective trial of corticosteroid therapy in active chronic hepatitis—Quart. J. Med.40, 1159, 1971.
Copenhagen Study Group for liver diseases: Sex, ascites and alcoholism in survival of patients with cirrhosis. Effect of prednisone—New Engl. J. Med.292, 271, 1974.
Czaja A. J., Ammon V. H., Summerskill W. H. J.: Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission—Gastroenterology78, 518, 1980.
Giusti G., Piccinino F., Ruggiero G., Galanti B., Lucchelli P. E., Manzillo G., Sagnelli E., Utili R.: Treatment of chronic active hepatitis with either prednisolone or c corucotrophin a controlled trial—Acta hepato gastroent.24, 131, 1977.
Lam K. C., Lai C. L., Ng R. P., Trepo C., Wu P. C.: Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis—New Engl. J. Med.304, 380, 1981.
Leevy C. M., Tygstrup N.: Standardization of nomenclature, diagnostic criterin and diagnostic methodology. In:Leevy C. M. (Ed.): Diseases of the liver and biliary tract. S. Karger, Rasel, 1976; p. 8.
Murray-Lion I. M., Stern R. B., Williams R.: Controlled trial of prednisone and azathioprine in active chronic hepatitis—Lanceti, 735, 1973.
Soloway R. D., Summerskill W. H. J., Baggenstoss A. H., Geall M. G., Gitnik G. L., Elveback L. R., Schoenfield L. J.: Clinical, biochemical and histological remission of severe chronic active hepatitis liver disease: a controlled study of treatment and early prognosis— Gastroenterology63, 820, 1972.
Tsuji T., Naito K., Tokuyama K., Okada T., Takata S., Aroki K., Shinohara T., Inoue J., Onoue K., Tsuchija M., Nozaki H., Nagashima H., Hamaya K.: Follow-up ten years after corticosteroid therapy for chronic active hepatitis—Acta hepato-gastroent.27 85, 1980.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Manzillo, G., Piccinino, F., Sagnelli, E. et al. Treatment of HBsAg-Positive chronic active hepatitis with corticosteroids and/or azathioprine. La Ricerca Clin. Lab. 13, 261–268 (1983). https://doi.org/10.1007/BF02904840
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02904840